BioLineRx Company Profile (NASDAQ:BLRX)

About BioLineRx

BioLineRx logoBioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BLRX
  • CUSIP:
Key Metrics:
  • Previous Close: $1.23
  • 50 Day Moving Average: $0.94
  • 200 Day Moving Average: $0.92
  • 52-Week Range: $0.71 - $1.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.87
  • P/E Growth: 0.00
  • Market Cap: $67.71M
  • Outstanding Shares: 56,423,000
  • Beta: 1.63
Profitability:
  • Return on Equity: -28.52%
  • Return on Assets: -26.52%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 15.25%
  • Quick Ratio: 15.25%
Additional Links:
Companies Related to BioLineRx:

Analyst Ratings

Consensus Ratings for BioLineRx (NASDAQ:BLRX) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $3.02 (151.67% upside)

Analysts' Ratings History for BioLineRx (NASDAQ:BLRX)
Show:
DateFirmActionRatingPrice TargetDetails
9/26/2016Roth CapitalReiterated RatingBuy$7.00View Rating Details
9/23/2016S&P Equity ResearchLower Price Target$1.24 -> $1.10View Rating Details
9/7/2016Maxim GroupReiterated RatingHold$1.00View Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$3.50 -> $3.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$3.50 -> $3.00View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for BioLineRx (NASDAQ:BLRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/11/2016Q216($0.07)($0.09)ViewListenView Earnings Details
5/17/2016Q116($0.08)($0.10)ViewListenView Earnings Details
3/10/2016Q415($0.06)($0.07)ViewListenView Earnings Details
11/16/2015Q315($0.08)($0.03)ViewListenView Earnings Details
8/20/2015Q215($0.10)($0.09)ViewListenView Earnings Details
5/18/2015Q115($0.10)($0.08)ViewListenView Earnings Details
11/10/2014Q314($0.17)($0.01)ViewN/AView Earnings Details
8/6/2014Q214($0.09)($0.12)ViewN/AView Earnings Details
5/20/2014Q114($0.11)($0.01)ViewN/AView Earnings Details
3/17/2014($0.15)($0.20)ViewN/AView Earnings Details
11/13/2013($0.18)($0.20)ViewN/AView Earnings Details
8/6/2013Q213($0.02)ViewN/AView Earnings Details
5/7/2013($0.02)($0.20)ViewN/AView Earnings Details
11/14/2012Q312($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioLineRx (NASDAQ:BLRX)
Current Year EPS Consensus Estimate: $-0.27 EPS
Next Year EPS Consensus Estimate: $-0.31 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.08)($0.08)($0.08)
Q2 20161($0.07)($0.07)($0.07)
Q3 20161($0.07)($0.07)($0.07)
Q4 20161($0.08)($0.08)($0.08)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioLineRx (NASDAQ:BLRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BioLineRx (NASDAQ:BLRX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for BioLineRx (NASDAQ:BLRX)
DateHeadline
stocksdaily.net logoAnalysts Set EPS Target of $-0.07 For BioLineRx Ltd. (NASDAQ:BLRX) - Stocks Daily (NASDAQ:BLRX)
www.stocksdaily.net - September 26 at 4:02 PM
rttnews.com logoFDA Approves AMGN's 1st Biosimilar, MRNS On Track, All Ears For DRRX, PTIE (NASDAQ:BLRX)
www.rttnews.com - September 26 at 8:37 AM
thestreet.com logoBioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement (NASDAQ:BLRX)
www.thestreet.com - September 24 at 8:07 AM
streetinsider.com logoUnusual 11 Mid-Day Movers 9/23: (IMPV) (BLRX) (TWTR) Higher; (ENPH) (APPS) (RAVE) Lower - StreetInsider.com (NASDAQ:BLRX)
www.streetinsider.com - September 23 at 3:20 PM
News IconShares Recorded Gapping Higher Pre-Market: BioLineRx, Ltd. (NASDAQ:BLRX) - Post News (NASDAQ:BLRX)
www.kentuckypostnews.com - September 23 at 3:20 PM
streetinsider.com logoBioLineRx (BLRX) Enters ESLD in-Licensing Agreement - StreetInsider.com (NASDAQ:BLRX)
www.streetinsider.com - September 23 at 3:20 PM
smarteranalyst.com logoCompany Update (NASDAQ:BLRX): BioLineRx Ltd. Presents Corporate Objectives at Investor Breakfast Meeting in NY - Smarter Analyst (NASDAQ:BLRX)
www.smarteranalyst.com - September 23 at 3:20 PM
insidermonkey.com logoWhy These 5 Stocks Are Winning Today (NASDAQ:BLRX)
www.insidermonkey.com - September 23 at 3:20 PM
finance.yahoo.com logo7:01 am BioLineRx announces in-licensing of novel treatment for liver failure conditions; second project in-licensed under strategic collaboration with Novartis (NVS (NASDAQ:BLRX)
finance.yahoo.com - September 23 at 8:58 AM
publicnow.com logoBioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic Collaboration (NASDAQ:BLRX)
www.publicnow.com - September 23 at 8:58 AM
streetinsider.com logoBioLineRx (BLRX) Updates on Corp. Objectives; Plans Ramp-up of Several BL-8040 Combo Phase 1bs (NASDAQ:BLRX)
www.streetinsider.com - September 22 at 4:02 PM
finance.yahoo.com logoBioLineRx Ltd. Presents Corporate Objectives at Investor Breakfast Meeting in NY (NASDAQ:BLRX)
finance.yahoo.com - September 22 at 4:02 PM
News IconBioLineRx Starts Phase 2a Combo Trial For Pancreatic Cancer (NASDAQ:BLRX) - Post News (NASDAQ:BLRX)
www.kentuckypostnews.com - September 21 at 8:25 AM
streetinsider.com logoBioLineRx (BLRX) Commences BL-8040 Combo Phase 2a in Pancreatic Cancer - StreetInsider.com (NASDAQ:BLRX)
www.streetinsider.com - September 21 at 8:25 AM
smarteranalyst.com logoCompany Update (NASDAQ:BLRX): Bioline RX Ltd Announces Initiation of Phase 2a Trial of BL-8040 in Combination ... - Smarter Analyst (NASDAQ:BLRX)
www.smarteranalyst.com - September 20 at 9:45 AM
publicnow.com logoBioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer (NASDAQ:BLRX)
www.publicnow.com - September 20 at 9:45 AM
stocksdaily.net logoCan BioLineRx Ltd. (NASDAQ:BLRX) Hit High Of $7? - Stocks Daily (NASDAQ:BLRX)
www.stocksdaily.net - September 13 at 5:31 PM
investingnews.com logoBioLineRx Hosts Investor Meeting (NASDAQ:BLRX)
investingnews.com - September 9 at 3:49 PM
streetinsider.com logoBioLineRx (BLRX) Announces Presentation of Positive BL-8040 Phase 2a Data in AML (NASDAQ:BLRX)
www.streetinsider.com - September 9 at 3:49 PM
News IconBioLineRx Ltd. to Host Investor Breakfast ... (NASDAQ:BLRX)
ih.advfn.com - September 9 at 3:49 PM
prnewswire.com logoBioLineRx Ltd. to Host Investor Breakfast Meeting September 22, 2016 in New York - PR Newswire (press release) (NASDAQ:BLRX)
www.prnewswire.com - September 9 at 8:46 AM
publicnow.com logoBioLineRx Ltd. to Host Investor Breakfast Meeting September 22, 2016 in New York (NASDAQ:BLRX)
www.publicnow.com - September 9 at 8:46 AM
streetinsider.com logoBioLineRx (BLRX) Announces Presentation of Positive BL-8040 Phase 2a Data in AML - StreetInsider.com (NASDAQ:BLRX)
www.streetinsider.com - September 8 at 7:58 AM
finance.yahoo.com logoBioLineRx Presents Final Results from Phase 2a Trial for Relapsed/Refractory AML at SOHO Conference (NASDAQ:BLRX)
finance.yahoo.com - September 8 at 7:58 AM
News IconBioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncol... (NASDAQ:BLRX)
ih.advfn.com - September 7 at 8:57 PM
News IconPlacing BioLineRx Ltd. (NASDAQ:BLRX) Shares Under the Microscope - Post News (NASDAQ:BLRX)
www.kentuckypostnews.com - September 7 at 3:52 PM
News IconShares Gapping Up Before the Open: BioLineRx, Ltd. (NASDAQ:BLRX) - Post News (NASDAQ:BLRX)
www.kentuckypostnews.com - September 7 at 12:37 PM
streetinsider.com logoBioLineRx (BLRX), Genentech Enter Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab - StreetInsider.com (NASDAQ:BLRX)
www.streetinsider.com - September 7 at 12:37 PM
publicnow.com logoBioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications (NASDAQ:BLRX)
www.publicnow.com - September 7 at 12:37 PM
marketwatch.com logoBioLineRx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York (NASDAQ:BLRX)
www.marketwatch.com - August 29 at 8:37 AM
streetinsider.com logoBioLineRx (BLRX), I-Bridge Capital Form New JV in China - StreetInsider.com (NASDAQ:BLRX)
www.streetinsider.com - August 27 at 8:40 AM
4-traders.com logoBioLineRx : and I-Bridge Capital Establish a New Drug Development Joint Venture in China (NASDAQ:BLRX)
www.4-traders.com - August 25 at 9:18 PM
News IconBioLineRx and I-Bridge Capital launch new joint venture (NASDAQ:BLRX)
www.pehub.com - August 25 at 3:55 PM
streetinsider.com logoBioLineRx (BLRX), I-Bridge Capital Form New JV in China (NASDAQ:BLRX)
www.streetinsider.com - August 25 at 8:44 AM
publicnow.com logoBioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture in China (NASDAQ:BLRX)
www.publicnow.com - August 25 at 8:44 AM
stocksdaily.net logoCan BioLineRx Ltd. (NASDAQ:BLRX) Meet Analysts Expectations? - Stocks Daily (NASDAQ:BLRX)
www.stocksdaily.net - August 20 at 3:54 PM
stocksdaily.net logoWill BioLineRx Ltd. (NASDAQ:BLRX) Surprise Analysts This Quarter? - Stocks Daily (NASDAQ:BLRX)
www.stocksdaily.net - August 14 at 8:41 AM
finance.yahoo.com logoBioLineRx downgraded by Maxim Group (NASDAQ:BLRX)
finance.yahoo.com - August 12 at 12:32 PM
finance.yahoo.com logoBioLineRx Reports Second Quarter 2016 Financial Results (NASDAQ:BLRX)
finance.yahoo.com - August 11 at 12:01 PM
4-traders.com logoBioLineRx : Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer (NASDAQ:BLRX)
www.4-traders.com - August 8 at 3:56 PM
publicnow.com logoBioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer (NASDAQ:BLRX)
www.publicnow.com - August 8 at 8:41 AM
publicnow.com logoBioLineRx to Report Second Quarter Results on August 11, 2016 (NASDAQ:BLRX)
www.publicnow.com - August 4 at 12:27 PM
marketexclusive.com logoNovartis AG (NYSE:NVS)’s Partner Bioline RX Announce In-Licensing Of Liver Fibrosis Project (NASDAQ:BLRX)
marketexclusive.com - August 3 at 3:54 PM
News IconNews Review - Bioline RX Ltd (NASDAQ:BLRX) - Hot Stocks Point (NASDAQ:BLRX)
www.hotstockspoint.com - August 2 at 8:41 AM
twst.com logoBioLineRX Ltd.: BioLineRx Announces In-licensing of Liver Fibrosis Project Under Strategic Collaboration (NASDAQ:BLRX)
www.twst.com - August 1 at 8:46 AM
publicnow.com logoBioLineRx Announces In-licensing of Liver Fibrosis Project Under Strategic Collaboration (NASDAQ:BLRX)
www.publicnow.com - August 1 at 7:21 AM
News IconBiolinerx Limited Ads (NASDAQ:BLRX) Short Interest Decreased By 42.65% - Consumer Eagle (NASDAQ:BLRX)
www.consumereagle.com - July 16 at 3:49 PM
News IconBiolinerx Limited Ads (NASDAQ:BLRX) Shorts Decreased by 42.65% After Short Covering - Press Telegraph (NASDAQ:BLRX)
presstelegraph.com - July 15 at 2:29 PM
News IconAnalyst Target and Average Rating Watch: BioLineRx Ltd. (NASDAQ:BLRX) - Press Telegraph (NASDAQ:BLRX)
presstelegraph.com - July 15 at 2:29 PM
News IconBioLineRx Ltd. (NASDAQ:BLRX) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:BLRX)
telanaganapress.com - July 13 at 3:53 PM

Social

BioLineRx (NASDAQ:BLRX) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff